Cargando…

Does initial 45Gy of pelvic intensity-modulated radiotherapy reduce late complications in patients with locally advanced cervical cancer? A cohort control study using definitive chemoradiotherapy with high-dose rate brachytherapy

BACKGROUND: Comparing initial 45 Gy of pelvic intensity-modulated radiation therapy (IMRT) and non-IMRT in terms of the late toxicities associated with advanced cervical cancer that has also been treated with definitive concurrent chemoradiotherapy and high-dose rate intracavitary brachytherapy (HDR...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Shang-Wen, Liang, Ji-An, Hung, Yao-Ching, Yeh, Lian-Shung, Chang, Wei-Chun, Lin, Wu-Chou, Chien, Chun-Ru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Versita, Warsaw 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3691093/ https://www.ncbi.nlm.nih.gov/pubmed/23801915 http://dx.doi.org/10.2478/raon-2013-0011

Ejemplares similares

Textural features of cervical cancers on FDG-PET/CT associate with survival and local relapse in patients treated with definitive chemoradiotherapy
por: Chen, Shang-Wen, et al.
Publicado: (2018)

Comparison of once daily radiotherapy to 60 Gy and twice daily radiotherapy to 45 Gy for limited stage small-cell lung cancer
por: Han, Dan, et al.
Publicado: (2015)

Chemoradiotherapy Combined with Brachytherapy for the Definitive Treatment of Esophageal Carcinoma
por: Mangesius, Julian, et al.
Publicado: (2023)

Effectiveness of image‐guided radiotherapy for locally advanced lung cancer patients treated with definitive concurrent chemoradiotherapy
por: Liang, Ji‐An, et al.
Publicado: (2020)

External beam radiotherapy with or without californium-252 neutron brachytherapy for treatment of recurrence after definitive chemoradiotherapy
por: Wu, Wen-an, et al.
Publicado: (2020)

Acute and late toxicities in localized prostate cancer patients treated with low-dose (125)I brachytherapy (110 Gy) in combination with external beam radiation therapy versus brachytherapy alone (160 Gy)
por: Mukai, Yuki, et al.
Publicado: (2018)

Optimal radiotherapy dose in cervical esophageal squamous cell carcinoma patients treated with definitive concurrent chemoradiotherapy: A population based study
por: Li, Chia‐Chin, et al.
Publicado: (2021)

Definitive hypofractionated radiotherapy for early glottic carcinoma: experience of 55Gy in 20 fractions
por: Ermiş, Ekin, et al.
Publicado: (2015)

Consolidative chemotherapy after definitive concurrent chemoradiotherapy for esophageal squamous cell carcinoma patients: a population based cohort study
por: Lin, Chen-Yuan, et al.
Publicado: (2022)

Brachytherapy in a Single Dose of 10Gy as an “in situ” Vaccination
por: Jarosz-Biej, Magdalena, et al.
Publicado: (2020)

Effectiveness of image‐guided radiotherapy for locally advanced esophageal squamous cell carcinoma patients treated with definitive concurrent chemoradiotherapy
por: Kuo, Yao‐Hung, et al.
Publicado: (2019)

A total EQD(2) greater than 85 Gy for trachea and main bronchus D(2cc) being associated with severe late complications after definitive endobronchial brachytherapy
por: Murakami, Naoya, et al.
Publicado: (2015)

A total EQD(2) greater than 85 Gy for trachea and main bronchus D(2cc) being associated with severe late complications after definitive endobronchial brachytherapy
por: Murakami, Naoya, et al.
Publicado: (2016)

Comparison of intensity-modulated radiotherapy vs 3-dimensional conformal radiotherapy for patients with non-metastatic esophageal squamous cell carcinoma receiving definitive concurrent chemoradiotherapy: A population-based propensity-score-matched analysis
por: Li, Chia-Chin, et al.
Publicado: (2018)

Neoadjuvant vs definitive concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma patients
por: Chen, Chih-Yi, et al.
Publicado: (2018)

Radiographic Number of Positive Pelvic Lymph Nodes as a Prognostic Factor in Cervical Cancer Treated With Definitive Concurrent Chemoradiotherapy or Intensity-Modulated Radiotherapy
por: Wang, Shih-Chang, et al.
Publicado: (2018)

Genomic Biomarkers of Survival in Patients with Adenocarcinoma of the Uterine Cervix Receiving Chemoradiotherapy
por: Lin, Ying-Chun, et al.
Publicado: (2020)

Definitive radiotherapy consisting of whole pelvic radiotherapy with no central shielding and CT-based intracavitary brachytherapy for cervical cancer: feasibility, toxicity, and oncologic outcomes in Japanese patients
por: Kusada, Takeaki, et al.
Publicado: (2020)

Nonmetastatic pancreatic cancer: Improved survival with chemoradiotherapy > 40 Gy after systemic treatment
por: Bachmayer, Sebastian, et al.
Publicado: (2018)

Chemotherapy alone versus definitive concurrent chemoradiotherapy for cT4b esophageal squamous cell carcinoma: a population-based study
por: Li, Chia-Chin, et al.
Publicado: (2021)

Equivalent dose in 2 Gy (EQD2) to pelvic lymph nodes using volume based prescription for three brachytherapy applicators — a dosimetric retrospective analysis
por: Revathy, T, et al.
Publicado: (2021)

Correction to: Definitive radiotherapy consisting of whole pelvic radiotherapy with no central shielding and CT-based intracavitary brachytherapy for cervical cancer: feasibility, toxicity, and oncologic outcomes in Japanese patients
por: Kusada, Takeaki, et al.
Publicado: (2023)

Dose gradient impact on equivalent dose at 2 Gy for high dose rate interstitial brachytherapy
por: Hannoun-Levi, Jean-Michel, et al.
Publicado: (2012)

Stereotactic body-radiotherapy boost dose of 18 Gy vs 21 Gy in combination with androgen-deprivation therapy and whole-pelvic radiotherapy for intermediate- or high-risk prostate cancer: a study protocol for a randomized controlled, pilot trial
por: Kim, Yeon Joo, et al.
Publicado: (2018)

Comparison of the effects of radiotherapy doses of 50.4 Gy and 60 Gy on outcomes of chemoradiotherapy for thoracic esophageal cancer: subgroup analysis based on the Comprehensive Registry of Esophageal Cancer in Japan from 2009 to 2011 by the Japan Esophageal Society
por: Nemoto, Kenji, et al.
Publicado: (2020)

Salvage surgery after definitive chemoradiotherapy through VATS for an initial unresectable locally advanced lung cancer: an alternative consolidative modality to radiotherapy?
por: Yu, Hsuan-Hsuan, et al.
Publicado: (2021)

The cost of elective nodal coverage in prostate cancer: Late quality of life outcomes and dosimetric analysis with 0, 45 or 54 Gy to the pelvis
por: Jensen, Garrett L., et al.
Publicado: (2022)

Clinical audit of dose-escalated radical radiotherapy for advanced cervical carcinoma using a pragmatic protocol (3 fractions of 8 Gy HDR brachytherapy)
por: Goswami, Jyotirup, et al.
Publicado: (2021)

Kidney Cell DNA Damage Caused By Combined Exposure To Volatile Anaesthetics and 1 Gy Or 2 Gy Radiotherapy Dose in Vivo
por: Benković, Vesna, et al.
Publicado: (2022)

Safety of image-guided radiotherapy in definitive radiotherapy for localized prostate cancer: a population-based analysis
por: Kuo, Yao-Hung, et al.
Publicado: (2021)

Dose reduction trial from 60 Gy in 10 fractions to 54 Gy in 9 fractions schedule in high-dose-rate interstitial brachytherapy for early oral tongue cancer
por: Akiyama, Hironori, et al.
Publicado: (2012)

The clinical outcomes of elderly esophageal cancer patients who received definitive chemoradiotherapy
por: Lu, Hao-Wei, et al.
Publicado: (2020)

Validation of an MRI-only planning workflow for definitive pelvic radiotherapy
por: O’Connor, Laura M., et al.
Publicado: (2022)

Intensity-modulated radiation therapy from 70Gy to 80Gy in prostate cancer: six- year outcomes and predictors of late toxicity
por: Jolnerovski, Maria, et al.
Publicado: (2017)

Toxicity of dose-escalated radiotherapy up to 84 Gy for prostate cancer
por: Rosenbrock, Johannes, et al.
Publicado: (2023)

Comparison of volumetric-modulated arc therapy using simultaneous integrated boosts (SIB-VMAT) of 45 Gy/55 Gy in 25 fractions with conventional radiotherapy in preoperative chemoradiation for rectal cancers: a propensity score case-matched analysis
por: Yamashita, Hideomi, et al.
Publicado: (2017)

Increased bone marrow SUVmax on 18F-FDG PET is associated with higher pelvic treatment failure in patients with cervical cancer treated by chemoradiotherapy and brachytherapy
por: Seban, Romain-David, et al.
Publicado: (2019)

High vs. low radiotherapy dose in locally advanced esophageal squamous cell carcinoma patients treated with neoadjuvant concurrent chemoradiotherapy: an endemic area population-based study
por: Li, Chia-Chin, et al.
Publicado: (2022)

Enterovaginal and colovesical fistulas as late complications of pelvic radiotherapy
por: Iwamuro, Masaya, et al.
Publicado: (2018)

Clinical impact of boost irradiation to pelvic lymph node in uterine cervical cancer treated with definitive chemoradiotherapy
por: Choi, Kyu Hye, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_l0nbf0qcatggtm1vfuocieqdlc